Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Tue, 06th Apr 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - Hires Anne Beal as non-executive director, starting May 6. Beal will replace Lynn Elsenhans as chair of the Corporate Responsibility Committee, and Elsenhans will stay on the board for an additional year to allow for a handover. Beal is founder and chief executive officer of AbsoluteJOI Skincare. She spent six years at Harvard Medical School and Massachusetts General Hospital, instructing in paediatrics.

----------

Assura PLC - Warrington, England-based primary care property investor - Jenefer Greenwood will retire as non-executive director at Assura's July 6 annual general meeting. Hires Emma Cariaga, Noel Gordon and Sam Barrell as new non-executive directors, starting on May 1. Cariaga is joint head of Canada Water Development on the executive committee of British Land Co PLC. Gordon was global managing director at consultants Accenture. For the UK National Health Service, he was chair of NHS Digital and a non-executive director of NHS England. Barrell is chief operating officer of the Crick Institute, which supports biomedical research.

----------

Rosslyn Data Technologies PLC - London-based cloud enterprise data analytics platform - Chief Executive Officer Roger Bullen steps down from board, effective immediately, but will remain as an adviser for six months. Bullen served for five years as CEO and chief financial officer. Chief Customer Officer Paul Watts is promoted to CEO. Watts joined Rosslyn back in August and before that was CEO of Blue Prism KK Japan, a robotic process automation company. Both Chair James Appleby and CFO Ash Mehta will take on additional responsibilities. Rosslyn also says it expects its results for the financial year ending April 30 to be in line with market expectations. It will issue a trading update in late May.

----------

Celtic PLC - Glasgow football club - Confirms that Dominic McKay will join Celtic on April 19 before replacing retiring Peter Lawwell as chief executive on July 1. Scottish Rugby confirmed that McKay will leave as chief operating officer on April 16, following a successful handover. McKay, who also was chair of the Guinness Pro14 annual rugby union competition, will join the Celtic board.

----------

Amryt Pharma PLC - London-based biopharmaceutical firm focused on rare and orphan diseases - Hires Sheila Frame as president for the Americas. Frame has held senior positions at Novartis AG, Bristol-Myers Squibb Co and AstraZeneca PLC.

----------

MyHealthChecked PLC - Cardiff-based consumer home-testing healthcare - Peter Dines steps down as non-executive director on Tuesday. Dines is chief operating officer of Mercia Asset Management PLC, whose funds have a 28% stake in MyHealthChecked. He is standing down to focus on other portfolio companies.

----------

Northamber PLC - Chessington, Surrey-based audio-visual and information technology distributor - Promotes Finance Director Tony Lee to board and hires Riccardo Reggio as a non-executive director, both from last Thursday. Lee re-joined Northamber in August of last year, having previously been finance director from 2003 to 2005. Reggio is a corporate strategy and acquisitions adviser who worked at Monitor Group for 15 years.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Jan 2022 14:39

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

Read more
22 Nov 2021 11:37

Amryt to delist from AIM, concentrate on Nasdaq trading

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday, with effect on 11 January.

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
19 Oct 2021 15:54

Amryt Pharma granted another two US patents

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S10' on Tuesday, as well as its recently-acquired and third commercial product 'Mycapssa'.

Read more
14 Sep 2021 07:32

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

Read more
6 Aug 2021 14:41

IN BRIEF: Amryt hikes guidance on record second quarter results

IN BRIEF: Amryt hikes guidance on record second quarter results

Read more
6 Aug 2021 12:02

Record second quarter sees Amryt lift guidance further

(Sharecast News) - Amryt Pharma reported record second quarter results on Friday, raising its full-year guidance, as revenue in the three months ended 30 June came in at $62.8m, up from $46.2m year-on-year.

Read more
29 Jul 2021 17:10

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

Read more
17 Jun 2021 14:34

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 11:26

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
5 May 2021 19:20

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

Read more
31 Mar 2021 11:50

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.